Gabay C, et al. - Authors ascertained whether or not interleukin (IL)-18 inhibition, using the recombinant human IL-18 binding protein, tadekinig alfa, was a therapeutic option in Adult-onset Still’s disease (AOSD) (a rare systemic autoinflammatory disease). They included the patients that were ≥18 years with active AOSD plus fever or C reactive protein (CRP) levels ≥10mg/L despite treatment with prednisone and/or conventional synthetic disease-modifying antirheumatic drugs (DMARDs). This is the first clinical study to determine this association. Findings suggested a favourable safety profile of tadekinig alfa and its association with early signs of efficacy in patients with AOSD.